Matinas BioPharma stock analysis
Matinas BioPharma (6LJ) Stock Price & Analysis
6LJ Stock Chart & Stats
- Day’s Range
- EUR 0.05 - EUR 0.05
- 52-Week Range
- EUR 0.05 - EUR 0.05
- Previous Close
- EUR 0.06
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 866.66K
- Enterprise Value
- EUR 1.94M
- Total Cash (Recent Filing)
- EUR 761.00K
- Total Debt (Recent Filing)
- EUR 6,000
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Minimal debt reduces solvency pressure and limits mandatory interest obligations while the company funds clinical development. This gives Matinas greater financial flexibility than a similarly unprofitable biotech with substantial leverage, although it does not remove the need for external capital.
Improving Losses And Cash Burn
The improvement in losses and cash burn indicates some progress in controlling spending relative to earlier periods. If sustained, this could extend the company’s operating runway and make future financing needs more manageable, even though cash generation remains negative and profitability has not been reached.
LNC Drug Delivery Platform
A platform focused on improving the delivery and tolerability of existing drugs can support multiple product candidates rather than a single therapeutic bet. That creates potential strategic breadth for clinical development, while the company’s clinical-stage status means this platform advantage remains uncommercialized.
Bears Say
No Revenue And Continuing Losses
The absence of meaningful revenue leaves Matinas dependent on financing, partnerships, or successful future commercialization to support operations. Continued sizeable losses also show that the business has not yet demonstrated operating leverage, making durable earnings generation contingent on advancing candidates into revenue-producing products.
Negative Cash Generation And Shrinking Equity
Persistent cash outflows consume the company’s capital base and increase reliance on external funding while clinical programs continue. The sharp decline in equity suggests limited financial resilience and raises the likelihood that future capital needs could materially affect ownership or constrain development if funding is unavailable.
NYSE American Listing Risk
The exchange notice creates a structural financing and market-access risk because continued listing depends on restoring compliance by the remediation deadline. Delisting proceedings could reduce investor access and make future capital raising more difficult, adding pressure to an already thin equity base.
Matinas BioPharma News
6LJ FAQ
What was Matinas BioPharma’s price range in the past 12 months?
What is Matinas BioPharma’s market cap?
When is Matinas BioPharma’s upcoming earnings report date?
How were Matinas BioPharma’s earnings last quarter?
Is Matinas BioPharma overvalued?
Does Matinas BioPharma pay dividends?
What is Matinas BioPharma’s EPS estimate?
How many shares outstanding does Matinas BioPharma have?
What happened to Matinas BioPharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Matinas BioPharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jerome D. Jabbour
- Employees
- 2
- Website
- www.matinasbiopharma.com
- Address
- 1545 Route 206 South, Bedminster, NJ, 07921, US
Matinas BioPharma (6LJ) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 3 | 4 |
| Technical Analysis | 2 | 1 | 0 |
| Moving Averages | 6 | 2 | 4 |














